Top

Supportive Care in Cancer

Published in:

Open Access 01-12-2021 | Diabetes | Original Article

Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis

Authors: Jialin Gu, Hong Lu, Chen Chen, Zhancheng Gu, Miao Hu, Ling Liu, Jialin Yu, Guoli Wei, Jiege Huo

Published in: Supportive Care in Cancer | Issue 12/2021

Abstract

Background

To identify the association between diabetes mellitus (DM) and the risk of chemotherapy-induced peripheral neuropathy (CIPN) through a systematic review and meta-analysis.

Methods

An electronic literature search was conducted in PubMed, Embase, Web of Science, the Wanfang database, the VIP Journals database (CQVIP), the China National Knowledge Infrastructure (CNKI) database, and the China Biology Medicine database (Sinomed) between January 2010 and January 2021. Articles were included if they investigated CIPN and DM. Stata 15.1 was used to analyze the data.

Results

We examined 8923 cancer patients from 25 studies comprising 9 cohort studies and 16 case–control studies. Meta-analysis showed that there was a statistically significant positive correlation between DM and CIPN (odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.38–1.85, P < 0.001). Egger’s test (P = 0.824) showed no evidence of publication bias. The positive associations did not significant differ by study type, study quality, evaluation instrument, and type of antineoplastic drug. Omission of any single study had little effect on the combined risk estimate. Little evidence of heterogeneity was observed.

Conclusion

This meta-analysis provides evidence of a significant positive association between DM and risk of CIPN. Furthermore, a more detailed evaluation is warranted for cancer patients with diabetes when they are treated with antineoplastic drugs that have the potential to cause peripheral neuropathy.

Available only for authorised users

Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63:419–437. https://doi.org/10.3322/caac.21204CrossRefPubMed

Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515. https://doi.org/10.1016/j.ejca.2008.04.018CrossRefPubMed

Boyette-Davis JA, Walters ET, Dougherty PM (2015) Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Manag 5:285–296. https://doi.org/10.2217/pmt.15.19CrossRefPubMed

Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 54:587–591. https://doi.org/10.3109/0284186X.2014.995775CrossRefPubMed

Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 33(30):3416–3422. https://doi.org/10.1200/JCO.2014.58.8533CrossRefPubMedPubMedCentral

Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31(21):2699–2707. https://doi.org/10.1200/JCO.2013.49.1514CrossRefPubMed

Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40:872–882. https://doi.org/10.1016/j.ctrv.2014.04.004CrossRefPubMed

Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB (2019) Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res 25:6295–6301. https://doi.org/10.1158/1078-0432.CCR-18-2152CrossRefPubMedPubMedCentral

Sałat K (2020) Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy. Pharmac Rep 72(3):486–507. https://doi.org/10.1007/s43440-020-00109-yCrossRef

10.

Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020CrossRefPubMed

11.

Kandula T, Park SB, Cohn RJ, Krishnan AV, Farrar MA (2016) Pediatric chemotherapy induced peripheral neuropathy: a systematic review of current knowledge. Cancer Treat Rev 50:118–128. https://doi.org/10.1016/j.ctrv.2016.09.005CrossRefPubMed

12.

Cliff J, Jorgensen AL, Lord R, Azam F, Cossar L, Carr DF, Pirmohamed M (2017) The molecular genetics of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Crit Rev Oncol Hematol 120:127–140. https://doi.org/10.1016/j.critrevonc.2017.09.009CrossRefPubMed

13.

Timmins HC, Mizrahi D, Li T, Kiernan MC, Goldstein D, Park SB (2021) Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. J Cancer Surviv. https://doi.org/10.1007/s11764-021-00988-xCrossRefPubMed

14.

Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549–1563. https://doi.org/10.2165/00003495-200363150-00003CrossRefPubMed

15.

Kus T, Aktas G, Kalender ME, Sevinc A, Kul S, Suner A, Ulker E, Camci C (2016) Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study. Support Care Cancer 24:1175–1179. https://doi.org/10.1007/s00520-015-2898-zCrossRefPubMed

16.

Chen C, Ding Q (2019) Effect of oxaliplatin on neurotoxicity of gastrointestinal tumors with diabetes mellitus. Diabetes New World 22(05):101–104

17.

Gaballah A, Shafik A, Elhusseiny K, Ashraf M (2018) Chemotherapy-induced peripheral neuropathy in Egyptian patients: single institution retrospective analysis. Asian Pac J Cancer Prev 19:2223–2227. https://doi.org/10.22034/APJCP.2018.19.8.2223CrossRefPubMedPubMedCentral

18.

Wang YQ, Yang XJ, Wei XC (2017) Analysis of factors affecting chemotherapy induced peripheral neurotoxicity. Tianjin Pharmacy 29(02):25–29

19.

de la Morena BP, Conesa MA, Gonzalez-Billalabeitia E, Urrego E, Garcia-Garre E, Garcia-Martinez E, Poves MZ, Vicente V, de la Pena FA (2015) Delayed recovery and increased severity of paclitaxel-induced peripheral neuropathy in patients with diabetes. J Natl Compr Canc Netw 13:417–423. https://doi.org/10.6004/jnccn.2015.0057CrossRef

20.

Ding XF (2015) Exploring the effect of diabetes on paclitaxel nerve damage. Diabetes New World 18(19):37–38

21.

Johnson C, Pankratz VS, Velazquez AI, Aakre JA, Loprinzi CL, Staff NP, Windebank AJ, Yang P (2015) Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci 349:124–128. https://doi.org/10.1016/j.jns.2014.12.041CrossRefPubMedPubMedCentral

22.

Xue YJ, Gu LP, Xue TG, Bian CF, Wang H, Cui LM (2013) Clinical study of paclitaxel-induced neurotoxicity in tumor patients with/without diabetes mellitus. J Hebei Med Univ 34(11):1440–1442

23.

Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol 34(25):3014–3022. https://doi.org/10.1200/JCO.2015.66.2346CrossRefPubMedPubMedCentral

24.

Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, Ng TR, Suen LKP, Chan CW, Yorke J, Lopez V (2019) Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 9:e01312. https://doi.org/10.1002/brb3.1312CrossRefPubMedPubMedCentral

25.

Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL (2018) Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res 24:3602–3610. https://doi.org/10.1158/1078-0432.CCR-18-0656CrossRefPubMedPubMedCentral

26.

Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S, Shibata Y, Esaki T, Ito M, Takayoshi K, Tsuchihashi K, Arita S, Ariyama H, Akashi K, Baba E (2018) The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. Cancer Chemother Pharmacol 82:625–633. https://doi.org/10.1007/s00280-018-3652-2CrossRefPubMed

27.

Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB (2017) clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res 23(19):5757–5768. https://doi.org/10.1158/1078-0432.CCR-16-3224CrossRefPubMedPubMedCentral

28.

Song SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im SA, Lee JY (2017) Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer 25:2241–2248. https://doi.org/10.1007/s00520-017-3631-xCrossRefPubMed

29.

Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327–333. https://doi.org/10.1007/s10549-016-3939-0CrossRefPubMedPubMedCentral

30.

Tanishima H, Tominaga T, Kimura M, Maeda T, Shirai Y, Horiuchi T (2017) Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. Support Care Cancer 25:1383–1389. https://doi.org/10.1007/s00520-016-3514-6CrossRefPubMed

31.

Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes JM, Lunet N (2016) Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study. Support Care Cancer 24:1571–1581. https://doi.org/10.1007/s00520-015-2935-yCrossRefPubMed

32.

Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M (2015) Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran. Asian Pac J Cancer Prev 16:7603–7606. https://doi.org/10.7314/apjcp.2015.16.17.7603CrossRefPubMed

33.

Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol 54(4):535–542. https://doi.org/10.3109/0284186X.2014.969846CrossRef

34.

Wang XY, Wang ZW, Yuan C, Li HY (2013) Clinical predictive factor of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. Chin J Pract Med 40(20):71–73

35.

Hashimoto N, Yokoyama K, Sadahira K, Ueda T, Tsukada Y, Okamoto S (2012) Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. Int J Hematol 96:758–763. https://doi.org/10.1007/s12185-012-1224-5CrossRefPubMed

36.

Kawakami K, Tunoda T, Takiguchi T, Shibata K, Ohtani T, Kizu J, Nishio M, Horai T, Hama T, Taguchi K (2012) Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. Oncol Res 20:179–185. https://doi.org/10.3727/096504012x13522227232192CrossRefPubMed

37.

Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G (2013) Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 21:1313–1319. https://doi.org/10.1007/s00520-012-1667-5CrossRefPubMed

38.

Uwah AN, Ackler J, Leighton JC Jr, Pomerantz S, Tester W (2012) The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 11:275–279. https://doi.org/10.1016/j.clcc.2012.05.002CrossRefPubMed

39.

Ramanathan RK, Rothenberg ML, de Gramont A, Tournigand C, Goldberg RM, Gupta S, Andre T (2010) Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol 21:754–758. https://doi.org/10.1093/annonc/mdp509CrossRefPubMed

40.

Soveri LM, Lamminmaki A, Hanninen UA, Karhunen M, Bono P, Osterlund P (2019) Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol 58:398–406. https://doi.org/10.1080/0284186X.2018.1556804CrossRefPubMed

41.

Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 38:3325–3348. https://doi.org/10.1200/JCO.20.01399CrossRefPubMed

42.

Melli G, Jack C, Lambrinos GL, Ringkamp M, Hoke A (2006) Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis 24:525–530. https://doi.org/10.1016/j.nbd.2006.08.014CrossRefPubMed

43.

Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, Peters GJ (2015) Platinum‐induced neurotoxicity and preventive strategies: past, present, and future. Oncologist 20(4):411–432. https://doi.org/10.1634/theoncologist.2014-0044CrossRefPubMedPubMedCentral

44.

Areti A, Yerra VG, Naidu V, Kumar A (2014) Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol 2:289–295. https://doi.org/10.1016/j.redox.2014.01.006CrossRefPubMedPubMedCentral

45.

Trecarichi A, Flatters SJL (2019) Chapter Five - Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy. In: Fernyhough P, Calcutt NA (eds) International review of neurobiology. Academic Press, pp 83–126

Title: Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis
Authors: Jialin Gu
Hong Lu
Chen Chen
Zhancheng Gu
Miao Hu
Ling Liu
Jialin Yu
Guoli Wei
Jiege Huo
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Diabetes
Cytostatic Therapy
Published in: Supportive Care in Cancer / Issue 12/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06321-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2021

Effects of parenteral nutrition and hydration on survival in advanced cancer patients with malignant bowel obstruction: secondary analysis of a multicenter prospective cohort study

Addressing sexual concerns of female breast cancer survivors and partners: a qualitative study of survivors, partners, and oncology providers about Internet intervention preferences

Increasing physical activity in Cancer Survivors through a Text-messaging Exercise motivation Program (ICanSTEP)

Analysis of factors associated with patient-reported physical functioning scores at discharge of allogeneic hematopoietic stem cell transplantation patients: a cross-sectional study

Effects of non-surgical periodontal therapy on the cytokine profile in gingival crevicular fluid of breast cancer patients with periodontitis undergoing chemotherapy

MASCC antiemetics in advanced cancer updated guideline

Keynote webinar | Spotlight on antibody–drug conjugates in cancer